MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention
of Thrombosis with Novel Antibody
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced
today that it has received a milestone payment from Novartis in connection with
the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The
antibody will be tested in the field of prevention of thrombosis. This is the
twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is
evaluating in clinical trials. Financial details were not disclosed.
"We are very pleased that another program from our collaboration with Novartis
has entered the clinical development stage," commented Dr. Marlies Sproll, Chief
Scientific Officer of MorphoSys AG. "During 2016, the MorphoSys pipeline has
matured significantly and currently includes more programs in clinical trials
than ever before. This again reflects the tremendous value of MorphoSys's
technologies and the resulting products, both in our partnered and proprietary
pipeline."
MorphoSys's collaboration with Novartis has resulted in twelve clinical programs
to date. In total, MorphoSys's proprietary and partnered clinical pipeline
currently comprises 27 unique antibody molecules, which are being evaluated in
more than 60 active clinical trials.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2024492/752425.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2024492]
Unternehmensinformation / Kurzprofil:
Datum: 04.07.2016 - 07:31 Uhr
Sprache: Deutsch
News-ID 481338
Anzahl Zeichen: 4359
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 377 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
